| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Review Article |
Department of Pharmacology, University of Washington, Seattle, Washington
Abstract
Abstract I. Introduction A. Definition of Phosphodiesterase Enzymes B. Early Studies C. Current Studies—Functional Pools of Cyclic Nucleotides Subserved by Specific Phosphodiesterases D. Why Phosphodiesterases Make Good Drug Targets E. Multiple Forms of Phosphodiesterases—Current Understanding F. Nomenclature G. Crystal Structures 1. Catalytic Domain Structures. 2. Glutamine Switch. 3. Regulatory Domain Structure. 4. Inhibitor Specificity. II. Phosphodiesterase Families A. Phosphodiesterase 1 Family 1. Overview. 2. Biochemistry/Structure. 3. Genetics/Splicing. 4. Localization. 5. Pharmacology/Function. B. Phosphodiesterase 2 Family 1. Overview. 2. Biochemistry/Structure. 3. Genetics/Splicing. 4. Localization. 5. Pharmacology/Function. C. Phosphodiesterase 3 Family 1. Overview. 2. Biochemistry/Structure. 3. Genetics/Splicing. 4. Localization. 5. Pharmacology/Function. D. Phosphodiesterase 4 Family 1. Overview. 2. Biochemistry/Structure. 3. Genetics/Splicing. 4. Localization. 5. Regulation by Phosphorylation. 6. Pharmacology/Function. E. Phosphodiesterase 5 Family 1. Overview. 2. Biochemistry/Structure. 3. Genetics/Splicing. 4. Localization. 5. Pharmacology/Function. F. Phosphodiesterase 6 Family 1. Overview. 2. Biochemistry/Structure. 3. Genetics/Splicing. 4. Localization. G. Phosphodiesterase 7 Family 1. Overview. 2. Biochemistry/Structure. 3. Genetics/Splicing. 4. Localization. 5. Pharmacology/Function. H. Phosphodiesterase 8 Family 1. Overview. 2. Biochemistry/Structure. 3. Genetics/Splicing. 4. Localization. 5. Pharmacology/Function. I. Phosphodiesterase 9 Family 1. Overview. 2. Biochemistry/Structure. 3. Genetics/Splicing. 4. Localization. 5. Pharmacology/Function. J. Phosphodiesterase 10 Family 1. Overview. 2. Biochemistry/Structure. 3. Localization. 4. Pharmacology/Function. K. Phosphodiesterase 11 Family 1. Overview. 2. Biochemistry/Structure. 3. Genetics/Splicing. 4. Localization. 5. Pharmacology/Function. III. Concluding Remarks: The Future of ''Phosphodiesterase Pharmacology''?
Cyclic nucleotide phosphodiesterases (PDEs) are enzymes that regulate the cellular levels of the second messengers, cAMP and cGMP, by controlling their rates of degradation. There are 11 different PDE families, with each family typically having several different isoforms and splice variants. These unique PDEs differ in their three-dimensional structure, kinetic properties, modes of regulation, intracellular localization, cellular expression, and inhibitor sensitivities. Current data suggest that individual isozymes modulate distinct regulatory pathways in the cell. These properties therefore offer the opportunity for selectively targeting specific PDEs for treatment of specific disease states. The feasibility of these enzymes as drug targets is exemplified by the commercial and clinical successes of the erectile dysfunction drugs, sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra). PDE inhibitors are also currently available or in development for treatment of a variety of other pathological conditions. In this review the basic biochemical properties, cellular regulation, expression patterns, and physiological functions of the different PDE isoforms will be discussed. How these properties relate to the current and future development of PDE inhibitors as pharmacological agents is especially considered. PDEs hold great promise as drug targets and recent research advances make this an exciting time for the field of PDE research.
This article has been cited by other articles:
|
|
 |
|
  T. M. Vinogradova, S. Sirenko, A. E. Lyashkov, A. Younes, Y. Li, W. Zhu, D. Yang, A. M. Ruknudin, H. Spurgeon, and E. G. Lakatta Constitutive Phosphodiesterase Activity Restricts Spontaneous Beating Rate of Cardiac Pacemaker Cells by Suppressing Local Ca2+ Releases Circ. Res., April 11, 2008; 102(7): 761 - 769. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Levallet, J. Levallet, and P.-J. Bonnamy FSH-induced phosphoprotein phosphatase 2A-mediated deactivation of particulate phosphodiesterase-4 activities is abolished after alteration in proteoglycan synthesis in immature rat Sertoli cells J. Endocrinol., April 1, 2008; 197(1): 45 - 54. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Dodd-o, M. L. Hristopoulos, K. Kibler, J. Gutkowska, S. Mukaddam-Daher, A. Gonzalez, L. E. Welsh-Servinsky, and D. B. Pearse The role of natriuretic peptide receptor-A signaling in unilateral lung ischemia-reperfusion injury in the intact mouse Am J Physiol Lung Cell Mol Physiol, April 1, 2008; 294(4): L714 - L723. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Lubamba, H. Lecourt, J. Lebacq, P. Lebecque, H. De Jonge, P. Wallemacq, and T. Leal Preclinical Evidence that Sildenafil and Vardenafil Activate Chloride Transport in Cystic Fibrosis Am. J. Respir. Crit. Care Med., March 1, 2008; 177(5): 506 - 515. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Horvath, V. Mericq, and C. A. Stratakis Chest-tube insertion. N. Engl. J. Med., February 14, 2008; 358(7): 750 - 750. [Full Text] [PDF]
|
|
|
|
 |
|
 F. D. Ivey, L. Wang, D. Demirbas, C. Allain, and C. S. Hoffman Development of a Fission Yeast-Based High-Throughput Screen to Identify Chemical Regulators of cAMP Phosphodiesterases J Biomol Screen, January 1, 2008; 13(1): 62 - 71. [Abstract] [PDF]
|
|
|
|
 |
|
 A. L. Burnett Molecular Pharmacotherapeutic Targeting of PDE5 for Preservation of Penile Health J Androl, January 1, 2008; 29(1): 3 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Wang, M. Ye, H. Robinson, S. H. Francis, and H. Ke Conformational Variations of Both Phosphodiesterase-5 and Inhibitors Provide the Structural Basis for the Physiological Effects of Vardenafil and Sildenafil Mol. Pharmacol., January 1, 2008; 73(1): 104 - 110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Rothkegel, P. M. Schmidt, D.-J. Atkins, L. S. Hoffmann, H. H. H. W. Schmidt, H. Schroder, and J.-P. Stasch Dimerization Region of Soluble Guanylate Cyclase Characterized by Bimolecular Fluorescence Complementation in Vivo Mol. Pharmacol., November 1, 2007; 72(5): 1181 - 1190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Schmidt, A. Stonkute, R. Juttner, S. Schaffer, J. Buttgereit, R. Feil, F. Hofmann, and F. G. Rathjen The receptor guanylyl cyclase Npr2 is essential for sensory axon bifurcation within the spinal cord J. Cell Biol., October 22, 2007; 179(2): 331 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Surapisitchat, K.-I. Jeon, C. Yan, and J. A. Beavo Differential Regulation of Endothelial Cell Permeability by cGMP via Phosphodiesterases 2 and 3 Circ. Res., October 12, 2007; 101(8): 811 - 818. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Laxman and J. A. Beavo Cyclic Nucleotide Signaling Mechanisms in Trypanosomes: Possible Targets for Therapeutic Agents Mol. Interv., August 1, 2007; 7(4): 203 - 215. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Bachteeva, E. Fock, E. Lavrova, S. Nikolaeva, S. Gambaryan, and R. Parnova Prostaglandin E2 inhibits vasotocin-induced osmotic water permeability in the frog urinary bladder by EP1-receptor-mediated activation of NO/cGMP pathway Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2007; 293(1): R528 - R537. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Zaccolo and M. A. Movsesian cAMP and cGMP Signaling Cross-Talk: Role of Phosphodiesterases and Implications for Cardiac Pathophysiology Circ. Res., June 8, 2007; 100(11): 1569 - 1578. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. V. Agostino, S. A. Plano, and D. A. Golombek Sildenafil accelerates reentrainment of circadian rhythms after advancing light schedules PNAS, June 5, 2007; 104(23): 9834 - 9839. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. K. Jackson, J. Ren, L. C. Zacharia, and Z. Mi Characterization of Renal Ecto-Phosphodiesterase J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 810 - 815. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Peter, S. L. C. Jin, M. Conti, A. Hatzelmann, and C. Zitt Differential Expression and Function of Phosphodiesterase 4 (PDE4) Subtypes in Human Primary CD4+ T Cells: Predominant Role of PDE4D J. Immunol., April 15, 2007; 178(8): 4820 - 4831. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Wang, Y. Liu, J. Hou, M. Zheng, H. Robinson, and H. Ke From the Cover: Structural insight into substrate specificity of phosphodiesterase 10 PNAS, April 3, 2007; 104(14): 5782 - 5787. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Palmer, S. L. Jimmo, D. R. Raymond, L. S. Wilson, R. L. Carter, and D. H. Maurice Protein Kinase A Phosphorylation of Human Phosphodiesterase 3B Promotes 14-3-3 Protein Binding and Inhibits Phosphatase-catalyzed Inactivation J. Biol. Chem., March 30, 2007; 282(13): 9411 - 9419. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Omori and J. Kotera Overview of PDEs and Their Regulation Circ. Res., February 16, 2007; 100(3): 309 - 327. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Fischmeister, L. R.V. Castro, A. Abi-Gerges, F. Rochais, J. Jurevicius, J. Leroy, and G. Vandecasteele Compartmentation of cyclic nucleotide signaling in the heart: the role of cyclic nucleotide phosphodiesterases. Circ. Res., October 13, 2006; 99(8): 816 - 828. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
 |
 |
 |
|
 |
 |
 |
